for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioSpecifics Technologies Corp.

BSTC.OQ

Latest Trade

57.75USD

Change

-0.71(-1.21%)

Volume

30,724

Today's Range

57.75

 - 

58.78

52 Week Range

52.59

 - 

73.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
58.46
Open
58.47
Volume
30,724
3M AVG Volume
1.12
Today's High
58.78
Today's Low
57.75
52 Week High
73.31
52 Week Low
52.59
Shares Out (MIL)
7.33
Market Cap (MIL)
428.53
Forward P/E
18.44
Dividend (Yield %)
--

Next Event

Q3 2019 Biospecifics Technologies Corp Earnings Release

Latest Developments

More

Biospecifics Technologies Q2 Earnings Per Share $0.87

Biospecifics Technologies Corp Reports First Quarter 2019 Financial And Operating Results

Biospecifics Technologies Corp Reports Q4 Earnings Per Share $0.84

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Industry

Biotechnology & Drugs

Contact Info

35 WILBUR ST

+1.516.5937000

http://www.biospecifics.com/

Executive Leadership

Ronald Edward Law

Principal Executive Officer

Patrick M. Caldwell

Principal Financial Officer, Principal Accounting Officer

Mark N. Wegman

Director

Toby Wegman

Director

Jennifer M. Chao

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

1.560

2017

1.550

2018

2.730

2019(E)

3.170
Price To Earnings (TTM)
19.47
Price To Sales (TTM)
12.24
Price To Book (MRQ)
3.89
Price To Cash Flow (TTM)
18.40
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
22.38
Return on Equity (TTM)
21.93

Latest News

BRIEF-Biospecifics Technologies Reports Q1 Earnings Per Share $0.54

* BIOSPECIFICS TECHNOLOGIES CORP. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Biospecifics Technologies Q4 Earnings Per Share $0.36

* . REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Biospecifics Technologies reports Q3 eps of $0.37

* Biospecifics Technologies Corp reports Q3 2017 financial results

BRIEF-BioSpecifics Technologies reports Q2 earnings per share $0.36

* BioSpecifics Technologies Corp reports second quarter 2017 financial results

BRIEF-Biospecifics Technologies reports Q1 earnings per share $0.46

* Biospecifics Technologies Corp. reports first quarter 2017 financial results

BRIEF-Biospecifics Technologies announces positive data from mid-stage study in patients with cellulite

* CCH was well-tolerated in actively treated subjects with most adverse events being mild to moderate in severity

BRIEF-Biospecifics Technologies reports Q3 earnings per share $0.42

* Biospecifics Technologies Corp - total revenue for Q3 ended September 30, 2016 was $6.9 million, compared to $6.3 million

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up